Valuation: Positron Corporation

Market Cap 63.06M 55.22M 50.98M 47.6M 89.61M 5.96B 91.65M 613M 237M 2.94B 237M 232M 10.21B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 61.93M 54.22M 50.06M 46.74M 87.99M 5.85B 90M 602M 233M 2.89B 233M 227M 10.03B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
47.44%
Yield 2024 *
-
Yield 2025 -
1 day+3.78%
1 week+6.08%
Current month+2.13%
1 month+2.13%
3 months-2.04%
6 months+23.31%
Current year+14.97%
1 week 1.63
Extreme 1.6334
1.94
1 month 1.56
Extreme 1.56
1.94
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 26/02/2018
Sales & Marketing - 23/06/2022
Corporate Officer/Principal 40 24/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+3.78%+6.08%+28.77%+25.49% 63.06M
+3.87%-2.07%-20.41%-26.81% 12.31B
+6.05%+1.12%+76.26%+8.81% 4.88B
+0.12%+2.60%+54.62%+93.36% 1.2B
+1.84%-3.02%-38.11%-66.74% 1.16B
+2.28%-8.34%-40.46%-50.50% 1.07B
+2.10%-6.05%-43.59% - 890M
+13.81%+3.20%+185.75%+183.77% 683M
+0.27%+16.36% - - 377M
+4.39%+14.08%-55.04%+243.66% 263M
Average +3.85%+1.30%+16.42%+51.38% 2.29B
Weighted average by Cap. +4.13%-0.39%+7.74%-5.32%

Financials

2024 2025
Net sales 588K 514K 475K 443K 835K 55.54M 854K 5.71M 2.21M 27.4M 2.21M 2.16M 95.14M 461K 404K 373K 348K 656K 43.63M 671K 4.49M 1.73M 21.52M 1.73M 1.69M 74.73M
Net income -2.38M -2.08M -1.92M -1.8M -3.38M -225M -3.46M -23.14M -8.93M -111M -8.93M -8.74M -385M -10.6M -9.28M -8.57M -8M -15.07M -1B -15.41M -103M -39.82M -495M -39.82M -38.95M -1.72B
Net Debt 1.42M 1.25M 1.15M 1.08M 2.02M 135M 2.07M 13.86M 5.35M 66.44M 5.35M 5.23M 231M -1.14M -995K -918K -858K -1.61M -107M -1.65M -11.05M -4.27M -52.99M -4.27M -4.17M -184M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
29/06/26 US$1.920 +3.78% 62,002
26/06/26 US$1.850 0.00% 27,900
25/06/26 US$1.850 +9.47% 70,017
24/06/26 US$1.690 -2.42% 42,681
23/06/26 US$1.732 -4.31% 87,181
  1. Stock Market
  2. Stocks
  3. POSC Stock